Profound Medical Valuation Multiples

Profound Medical Overview

About Profound Medical

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Founded

2014

HQ

Employees

131

Website

profoundmedical.com

Sectors

Medical DevicesBioTechLongevity

Financials (LTM)

Revenue: $20M

EBITDA: ($35M)

EV

$183M

Valuation Multiples

Multiples.vc

Start free trial

Profound Medical Financials

Profound Medical reported last 12-month revenue of $20M and negative EBITDA of ($35M).

In the same LTM period, Profound Medical generated $14M in gross profit, ($35M) in EBITDA losses, and had net loss of ($40M).

Profound Medical P&L

In the most recent fiscal year, Profound Medical reported revenue of $16M and EBITDA of ($37M).

Profound Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Profound Medical Stock Performance

Profound Medical has current market cap of $238M, and enterprise value of $183M.

Profound Medical's stock price is $6.57.

Profound Medical Valuation Multiples

Profound Medical trades at 9.1x EV/Revenue multiple, and (5.3x) EV/EBITDA.

Profound Medical Financial Valuation Multiples

As of April 11, 2026, Profound Medical has market cap of $238M and EV of $183M.

Equity research analysts estimate Profound Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Profound Medical has a P/E ratio of (5.9x).

Profound Medical Margins & Growth Rates

Profound Medical's revenue in the last 12 month grew by 77%.

Profound Medical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Profound Medical's rule of 40 is (7%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Profound Medical's rule of X is 127% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Profound Medical Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Profound Medical M&A Activity

Profound Medical acquired XXX companies to date.

Last acquisition by Profound Medical was on XXXXXXXX, XXXXX. Profound Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Profound Medical Investment Activity

Profound Medical invested in XXX companies to date.

Profound Medical made its latest investment on XXXXXXXX, XXXXX. Profound Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).